AR120055A1 - Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal - Google Patents
Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renalInfo
- Publication number
- AR120055A1 AR120055A1 ARP200101648A ARP200101648A AR120055A1 AR 120055 A1 AR120055 A1 AR 120055A1 AR P200101648 A ARP200101648 A AR P200101648A AR P200101648 A ARP200101648 A AR P200101648A AR 120055 A1 AR120055 A1 AR 120055A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- patients
- methods
- kidney failure
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proporcionan métodos para al tratamiento de la enfermedad de Fabry en un paciente que tiene insuficiencia renal. Determinados métodos comprenden administrar al paciente de aproximadamente 100 mg a aproximadamente 300 mg de equivalente de base libre de migalastat o sal del mismo a una frecuencia mayor de una vez cada dos días, tal como una vez cada cuatro o siete días. Determinados métodos comprenden medir la liso-Gb3 y/o el migalastat en una o más muestras de plasma del paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120055A1 true AR120055A1 (es) | 2022-02-02 |
Family
ID=71950725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101648A AR120055A1 (es) | 2019-06-11 | 2020-06-11 | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (es) |
| EP (1) | EP3982962A1 (es) |
| JP (1) | JP2022536687A (es) |
| KR (1) | KR20220019796A (es) |
| CN (1) | CN114423427A (es) |
| AR (1) | AR120055A1 (es) |
| AU (1) | AU2020291002A1 (es) |
| BR (1) | BR112021024886A2 (es) |
| CA (1) | CA3141226A1 (es) |
| CL (1) | CL2021003280A1 (es) |
| EA (1) | EA202290024A1 (es) |
| IL (1) | IL288677A (es) |
| MX (1) | MX2021015352A (es) |
| TW (1) | TW202112372A (es) |
| WO (1) | WO2020252129A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2533050B3 (en) | 2006-05-16 | 2015-06-24 | Amicus Therapeutics, Inc. | Treatment Options For Fabry Disease |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| KR102631805B1 (ko) | 2017-05-30 | 2024-01-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| CN114423428A (zh) | 2019-08-07 | 2022-04-29 | 阿米库斯治疗学公司 | 治疗在gla基因中具有突变的患者的法布里病的方法 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| EP2142197A4 (en) | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| CA2829947C (en) * | 2011-03-11 | 2019-01-15 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
| MX2018007669A (es) * | 2016-07-19 | 2018-09-12 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. |
| BR112019013920A2 (pt) * | 2017-01-05 | 2020-02-04 | Protalix Ltd | método para tratar doença de fabry, e, forma unitária de dosagem. |
| KR102631805B1 (ko) * | 2017-05-30 | 2024-01-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
-
2020
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en active Pending
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 JP JP2021573404A patent/JP2022536687A/ja active Pending
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en unknown
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020291002A1 (en) | 2022-01-06 |
| US20220313670A1 (en) | 2022-10-06 |
| WO2020252129A1 (en) | 2020-12-17 |
| MX2021015352A (es) | 2022-04-06 |
| BR112021024886A2 (pt) | 2022-01-25 |
| IL288677A (en) | 2022-02-01 |
| CA3141226A1 (en) | 2020-12-17 |
| CN114423427A (zh) | 2022-04-29 |
| CL2021003280A1 (es) | 2022-10-07 |
| KR20220019796A (ko) | 2022-02-17 |
| EA202290024A1 (ru) | 2022-03-14 |
| TW202112372A (zh) | 2021-04-01 |
| JP2022536687A (ja) | 2022-08-18 |
| EP3982962A1 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| CY1122604T1 (el) | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
| AR111491A1 (es) | Métodos para tratar enfermedades pediátricas | |
| DOP2014000258A (es) | Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro | |
| AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA202190291A1 (ru) | Комбинированная терапия для лечения рака | |
| UA109966C2 (uk) | Спосіб лікування латентної ішемічної хвороби серця у хворих на бронхіальну астму |